FDA: Prasugrel [Regulatives / Guidelines]

posted by intuitivepharma – India, 2013-12-24 07:38 (4563 d 18:30 ago) – Posting: # 12100
Views: 30,749

Dear Helmut,

Thanks for the reply. In such a precarious situation my only hope to defend the ANDA would be based on the following assumptions.

The guidance recommendations are nonbinding
The demonstration of bioequivalence to an active metabolite is more “closer” to the actual clinical situation than demonstration of bioequivalence to an inactive metabolite.

Can any one let know why for Prasugrel, bioequivalence is based on inactive metabolite and active metabolite PK is submitted as supportive data. The condition that data on active metabolite is required implies that it can be quantified. Enlighten me if I am missing some thing over here.

Thanks & Regards,
IP.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
177 visitors (0 registered, 177 guests [including 60 identified bots]).
Forum time: 03:09 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5